Furthermore, there were no significant differences between the two groups in good neurological outcome (OR 0.97, 95% CI: 0.76 to 1.25, I2 = 0%; Fig. 1B), the incidence of arrhythmia (OR 0.89, 95% CI: 0.39 to 2.05, I2 = 61%; Fig. 1C), need for renal replacement therapy (OR 0.74, 95% CI: 0.27 to 2.03, I2 = 51%; Fig. 1D) and the levels of neuron-specific enolase at 48 h (MD 0.53, 95% CI: −0.09 to 0.15, I2 = 0%; Fig. 1E). The gene discussed is ENO2; the disease is Arrhythmia.